Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

Indian equity markets snapped a four-session losing streak to end in positive territory on Tuesday, driven by gains in auto ...

The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...

Biocon and Zydus Lifesciences are in the spotlight with fresh regulatory approvals fueling bullish analyst sentiment and renewed retail interest. Biocon shares rose 2% on Wednesday after its ...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...